On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xadago, 50 mg and 100 mg, film-coated tablet intended for the treatment of Parkinson’s disease. The active substance of Xadago is safinamide, …

Parkinsons Disease: Positive opinion by the CHMP issued recommending the granting of a marketing authorisation for Safinamide (Xadago) Read more »